Journal
LEUKEMIA & LYMPHOMA
Volume 53, Issue 7, Pages 1318-1320Publisher
INFORMA HEALTHCARE
DOI: 10.3109/10428194.2011.654116
Keywords
Lenalidomide; multiple myeloma; elderly patient
Categories
Ask authors/readers for more resources
Few data are available on the efficacy of the combination of lenalidomide plus dexamethasone (Len/Dex) in very elderly patients above 75 years of age with relapsed multiple myeloma (MM). We report here a single-center series of 45 consecutive patients aged 75 years or older with relapsed MM treated with this combination. The overall response rate was 62% and the median progression-free survival was 14 months, which compares favorably to that described in the two pivotal prospective studies that formed the basis for the approval of Len/Dex in the relapse setting. Our study confirms that Len/Dex is an effective combination in very elderly patients with relapsed MM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available